Interleukin-1α induces immunosuppression by mesenchymal stem cells promoting the growth of prostate cancer cells

Cheng, Jiwen; Li, Ling; Liu, Yan; Wang, Zhirou; Zhu, Xiaodong; Bai, Xianzhong

doi:10.3892/mmr.2012.1019

Cited by 48 publications

(33 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study of breast cancer, granzyme B release by CTLs was significantly reduced in the presence of MSCs. Significant reductions in the responses of NK cells and CTLs were observed with corresponding increases of TGF-β1 and T regs in the presence (vs. absence) of MSCs and resultant survival and expansion of the cancer cells [3,5].…”

Section: N O T F O R D I S T R I B U T I O N Regulatory T Cells (T Rementioning

confidence: 98%

Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases

Chang¹,

Schwertschkow²,

Nolta³

et al. 2015

CCDT

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) are known to be the helpers for the healing of tissue damage, often referred to as ambulatory cells. However, MSCs are also recruited by cancer cells to similarly aid in tumor growth and progression. In this review, some of the key steps in cancer progression and metastases are described including the various steps in which MSCs participate and may play important roles. MSCs aid in cancer cells' ability to evade immune attack, while promoting tumor angiogenesis, even being counter-acting against chemotherapeutics and other drugs used to fight various cancers. Furthermore, MSCs participate in many of the crucial steps in invasion and metastasis, including stimulating the epithelial-mesenchymal transition (EMT) and induction of stem-like properties that allow cancer stem cells to increase their survivability through the circulation. These steps are described in detail. Differences between circulating tumor cells (CTCs) and cancer stem cells (CSCs) are discussed, along with descriptions of the formation of a pre-metastatic niche, the role of exosomes from both cancer cells and MSCs in metastasis and tumor reseeding (self-seeding). More and more, MSCs are being proposed as a promising tumor targeting drug-delivery tool. In order to fulfill this promise, further understanding of the precise roles that MSCs play in the process of cancer metastases must be achieved, in attempting to create remedies that will improve the outcome of available therapeutics.

show abstract

Section: N O T F O R D I S T R I B U T I O N Regulatory T Cells (T Rementioning

confidence: 98%

Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases

Chang¹,

Schwertschkow²,

Nolta³

et al. 2015

CCDT

View full text Add to dashboard Cite

show abstract

“…For example MSCs produce CXCL7 which in turn induce the synthesis of IL8, a strong inducer of CSC self-renewal capability [35]. In addition, IL-1α which is present in the tumor environment [36] makes MSC promote the growth of cancer cells [37]. On the other hand, MSCs, mainly through their ability to recruit T-reg, can suppress the migration and proliferation of peripheral blood mononuclear cells (PBMC) and inhibit NK and cytotoxic T-cell (CTL) functions [38].…”

Section: Immunogenicity Of Mesenchymal Stem Cellsmentioning

confidence: 99%

Do Cancer Stem Cells have an Immunomodulatory Role Different from the Bulk of Tumor Cells?

Ghebeh

Al‐Alwan²

2013

J Carcinogene Mutagene

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide. In normal settings, the immune system is responsible for clearing cancer cells from our body. However, many patients develop immune tolerance to tumor cells through upregulation of immune regulatory molecules, release of immune suppressive factors in the tumor microenvironment and/or recruitment of regulatory/suppressive cells that impede the function of other fully activated effector immune cells. In spite of significant progress that have been achieved in increasing our understanding in this field, it is unknown whether all tumor cells exert similar inhibitory effect on the immune system or only specific subset(s) of tumor cells possess this feature.There is accumulating evidence that cancer is originated and sustained by a small population of cells called "Cancer Stem Cells (CSCs)". These cells share many characteristics of the normal stem cells including the selfrenewing ability. Thus, it is possible that they also have the immune privilege properties of normal stem cells. At least this has been shown to be the case for two types of cancers: melanoma and glioma.In this report we will review the role of CSCs in the creation of immune suppressive microenvironment which finally leads to tumor escape from the immune system surveillance.

show abstract

“…Several investigations have revealed that circulating BMderived adult stem/progenitor cells, including hematopoietic stem/progenitor cells, mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs) and/or myeloid cells may be recruited at prostatic inflammatory lesions and contribute to the PC development and metastases [86][87][88][89][90][91][92][93] . In fact, although BM-derived adult stem/progenitor cells appear to play only minimal roles in prostate epithelial regeneration after severe prostate inflammation and glandular disruption via cell fusion with prostate epithelial cells or transdifferentiation into prostate epitheliallike cells, they can induce immunosuppressive and angiogenic effects that promote prostate carcinogenesis [86][87][88][89][90][91][92][93] .…”

Section: Implications Of Bm-derived Adult Stem/progenitor Cells In Thmentioning

confidence: 99%

Development of animal models underlining mechanistic connections between prostate inflammation and cancer

Mimeault¹

2013

WJCO

View full text Add to dashboard Cite

The characterization of animal models has indicated that the genetic, dietary and environmental factors and hormonal imbalance may influence the risk to develop prostate inflammatory lesions and prostate cancer (PC) confirming human epidemiologic data. It is now established that the prostate inflammatory response typically results in major changes in the local microenvironment of epithelial cells of the prostate gland, including an intense stromal remodeling, activation of fibroblasts, infiltration of immune cells such as mast cells, macrophages and B and T lymphocytes and collagen deposition. The immune cells recruited at prostate inflammatory lesions and myofibroblasts may contribute to the release of numerous pro-inflammatory cytokines and chemokines that in turn can promote the oxidative stress, genomic instability and proliferation of epithelial cells. The accumulation of additional genetic and/or epigenetic alterations in prostatic stem/progenitor cells may subsequently culminate to their malignant transformation and PC initiation and progression and more particularly with advancing age. The potential mechanistic relationships between the molecular events associated with the persistent inflammatory response and prostate carcinogenesis have important implications for optimizing the current therapies against different prostatic disorders and PCs.

show abstract

Interleukin-1α induces immunosuppression by mesenchymal stem cells promoting the growth of prostate cancer cells

Cited by 48 publications

References 25 publications

Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases

Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases

Do Cancer Stem Cells have an Immunomodulatory Role Different from the Bulk of Tumor Cells?

Development of animal models underlining mechanistic connections between prostate inflammation and cancer

Contact Info

Product

Resources

About